Amgen Inc.

Medarex Inc.

Amgen Fremont Inc.

Bioatla, Inc.

William James Boyle

Frank J Calzone

David L Lacey

Ming-Shi Chang

Andrew A Welcher

Gary M Fox

Timothy D Bartley

Vann P Parker

Haichun Huang

Jose Corvalan

Francis Hall Martin

Hailing Hsu

C Geoffrey Davis

Frank Martin

Ella Magal

Richard A Lindberg

Eugene Medlock

Scott Kenneth Wooden

Robin L Elliott

Jay Milton Short

Gerhard Johann Frey

Hwai Wen Chang

John Kevin Sullivan

Rajendra V Deshpande

Ming-shi Chang

Geoffrey C Davis

John J Sullivan

Geoffrey Davis

Anna Hitz

Jose R Corvalan

John K Sullivan

An anti-IL-22 antibody or antibody fragment that binds to both human IL-22 and a mammalian IL-22 as well as modified anti-IL-22 antibodies and antibody fragments. Pharmaceutical compositions and kits comprising the antibody or antibody fragment are also provided. Also provided are methods for treatment of various IL-22 mediated conditions and diseases.

Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof

Anti-CD22 antibodies, including isolated nucleic acids that encode at least one such anti-CD22 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Anti-CD22 antibodies

Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.

Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.

Methods for treating bone loss with antibodies to OPGL

Compositions comprising polynucleotides encoding heavy and light chains of antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of making such antibodies are described.

Polynucleotides encoding heavy and light chains of antibodies to OPGL

A novel polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget's disease are also provided.

Methods for decreasing osteoclast formation or bone resorption using an antibody to osteoprotegerin binding protein

A novel polypeptide, osteoprotegerin binding protein, involved in osteoclast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog, or derivative thereof, vectors and host cells for production, and binding assays are described. Antibodies specifically binding osteoprotegerin binding protein are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget's disease are also provided.

Antibodies to osteoprotegerin binding proteins

The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.

Osteoprotegerin

The present invention provides a purified polynucleotide encoding a novel polypeptide, designated Fhm, which belongs to the TNF gene superfamily; to purified Fhm polypeptide molecules; to antibodies that bind Fhm; to materials comprising such molecules; and to methods of using such molecules.

Fhm a novel member of the TNF ligand supergene family: materials and methods for interaction modulators

Antibodies to OPGL

Osteoprotegerin binding proteins

The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis. Methods of treatment are described using the polypeptides in conjunction with various agents, including IL-1 inhibitors, TNF-&#x3b1; inhibitors, and serine protease inhibitors.

Combination therapy for conditions leading to bone loss

Fhm, a novel member of the TNF ligand supergene family

Growing community of inventors

Moorpark, CA, United States of America

William James Boyle